Comparing Decision Diagnostics (OTCMKTS:DECN) & Talkspace (NASDAQ:TALK)

Talkspace (NASDAQ:TALK) and Decision Diagnostics (OTCMKTS:DECN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Volatility and Risk

Talkspace has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Decision Diagnostics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Valuation and Earnings

This table compares Talkspace and Decision Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talkspace	$228.87 million	3.83	$7.79 million	$0.01	523.00
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A

Talkspace has higher revenue and earnings than Decision Diagnostics.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Talkspace and Decision Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talkspace	1	7	1	0	2.00
Decision Diagnostics	0	0	0	0	0.00

Talkspace currently has a consensus target price of $5.56, indicating a potential upside of 6.36%. Given Talkspace’s stronger consensus rating and higher probable upside, analysts clearly believe Talkspace is more favorable than Decision Diagnostics.

Institutional and Insider Ownership

57.4% of Talkspace shares are held by institutional investors. 23.5% of Talkspace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Talkspace and Decision Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talkspace	0.49%	1.03%	0.88%
Decision Diagnostics	N/A	N/A	N/A

Summary

Talkspace beats Decision Diagnostics on 9 of the 10 factors compared between the two stocks.

About Talkspace

Talkspace, Inc. operates as a virtual behavioral healthcare company in the United States. The company offers psychotherapy and psychiatry services through its platform to individuals, enterprises, and health plans and employee assistance programs. It provides text, audio, and video-based psychotherapy from licensed therapists. The company offers Talkspace Employee Assistance Program (EAP) and Talkspace Behavioral Health plan (BH) that provides online therapy to members through BH and EAP offerings; and Talkspace for Business for members to access its platform services on a benefit plan paid by the enterprise. It serves its platform through third-party platforms or marketplace, such as Apple App Store and Google Play App Store. Talkspace, Inc. was founded in 2012 and is headquartered in New York, New York.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.